Autopsy report · NCT02630186

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

“The study terminated before Phase 1 was completed. This study was reprioritized within the rociletinib development program.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 1 year 6 months before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 1 year 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Clovis Oncology, Inc.

Sponsor type

Industry

Conditions

Non-small Cell Lung Cancer

Interventions

Rociletinib; MPDL3280A

Participants

3

Sites

1

Countries

United States

Trials that died the same way

• PFC Sigma Fixed and Mobile Knee Study
  “The study was terminated at the point the primary endpoint and early milestones were reached and because long term outcomes were available from other sources” (61% match in meaning)
• A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer
  “This is phase I/II study, phase I study completed, phase II study started and enrolled 1 patient. Company strategy consideration to terminated phase 2 study finally.” (61% match in meaning)
• Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes
  “Due to lack of accrual the study was formally terminated on 01-JUL-2020. Primary Completion and Study Completion Dates have been revised based accordingly based on respective definitions” (59% match in meaning)
• A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
  “The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical benefit. This decision was not based on any new safety concerns.” (59% match in meaning)
• Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)
  “The study was terminated based on review of Phase 2 efficacy data” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.